Austedo Oral tablet
Israel's Teva gets China's green light for Huntington's treatment | The Times of Israel
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
AUSTEDO- deutetrabenazine tablet, coated AUSTEDO- deutetrabenazine kit
Teva takes on Neurocrine with TD nod for Austedo | Fierce Pharma
Yo-Bio on Twitter: "$TEVA #Austedo have no black box warning for tardive dyskinesia. Only for HD (Read about HD and you will understand way). $NBIX #INGREZZA https://t.co/lXnoHCEUAA" / Twitter
Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® (deutetrabenazine) tablets
Teva's Austedo, struggling from a pandemic slowdown, needs huge gains to meet 2021 projections | Fierce Pharma
jabo - Teva Austedo Academy
Deutetrabenazine - Wikipedia
Teva's Austedo Fails a Pair of Tourette Syndrome Trials – PharmaLive
FDA expands use of Austedo to tardive dyskinesia in adults
AUSTEDO® (deutetrabenazine) tablets: Tardive Dyskinesia and Huntington's Chorea Treatment
Austedo for Huntington's disease: Teva Pharmaceuticals has found a nifty way to keep drugs in your body for longer — Quartz
Punit on Twitter: "Teva hiked the price of #Austedo by ~6% in Jan.2021 Cost of treatment in US~ $60,000 a yr/patient 9MFY20 sales~ $451M (up 64% vs 2019) Tardive dyskinesia affects~ 500,000
FDA approves first deuterated drug
Austedo - FDA prescribing information, side effects and uses
Austedo - FDA prescribing information, side effects and uses
Teva settlement prevents Lupin from launching its Austedo generic until 2033 | Fierce Pharma
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha
China Approves Austedo for Huntington's-related Chorea
Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington's Disease - Clinical Trials Arena
2020 Pharma Choice DTC/DTP Silver Winner Intouch Group and Teva | PM360
Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease
Teva Reports Second Quarter 2021 Financial Results | Business Wire
Starting Patients | AUSTEDO® (deutetrabenazine) tablets
Teva's Austedo is first 'heavy hydrogen' drug to win US FDA approval
